Micro Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Withdraws its 510(k) submission for its Embolyx liquid embolic system for the treatment of arteriovenous malformations (AVMs) and head and neck tumors. The San Clemente, California-based firm, which says it is in discussions with FDA regarding a study design, intends to submit an IDE for further clinical evaluations. Additional studies related to aneurysms and peripheral vascular applications are expected. More than 40 AVM treatment procedures have been performed to date at sites in Los Angeles, Mexico City and Buenos Aires. An additional 10-patient trial to evaluate Embolyx in the pre-operative treatment of hypervascular tumors was recently initiated at UCLA Medical Center
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.